- Open Access
Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy
© Palermo et al; licensee BioMed Central Ltd. 2005
- Received: 13 June 2005
- Accepted: 31 August 2005
- Published: 31 August 2005
Vitiligo is a relatively common progressive depigmentary condition that is believed to be due to the autoimmune-mediated loss of epidermal melanocytes. High frequencies of self-reactive T lymphocytes directed toward melanocyte differentiation antigens are found in vitiligo patients and might be directly responsible for the pathogenesis of the disease. An interesting aspect of vitiligo is its relation to melanoma: cytotoxic T lymphocytes directed to self antigens shared by normal melanocytes and melanoma cells are found in both conditions, but the resulting immune reactions are completely different. From this standpoint, the selective destruction of pigment cells that occurs in cases of vitiligo is the therapeutic goal sought in melanoma research.
Presentation of the hypothesis
Our working hypothesis is that vitiligo patients might represent a unique source of therapeutic cells to be used in allo-transfer for HLA-matched melanoma patients. The adoptive transfer of ex-vivo generated autologous tumor-specific T cells is a therapy that has met with only limited success, essentially because of inability to isolate therapeutically valuable T cells from the majority of tumor patients. Ideally, model systems where strong and efficient responses against the same (tumor) antigens are achieved would represent a better source of therapeutic cells. We believe it is possible to identify one such model in the melanoma-vitiligo dichotomy: T lymphocytes specific for different melanocyte differentiation antigens are found in vitiligo and represent the effective anti-melanocyte reactivity that is often ineffective in melanoma.
Testing the hypothesis
Melanocyte-specific T cell clones can be isolated from the peripheral blood of vitiligo patients and tested for their capacity to efficiently expand in vitro without loosing their cytotoxic activity and to migrate to the skin. Cytotoxicity against melanoma patients' non-tumor cells can also be tested. In addition, it would be interesting to attempt an in vivo animal model. If the results obtained from these validation steps will be satisfactory, it might be possible to plan the clinical grade preparation of relevant clones for transfer.
Implications of the hypothesis
When translated into a clinical trial, the possibility of in vitro selecting few effective tumor-specific T cell clones for infusion, inherent with this approach, could enhance the therapeutic graft-versus-tumor effect while possibly decreasing the risk of graft-versus-host disease.
- Melanoma Patient
- Therapeutic Cell
- Vitiligo Patient
Vitiligo is a common skin disease characterized by the development of white macules and patches associated with local melanocyte loss . Its etiology is not completely known, but the observation of circulating antimelanocytic antibodies and of lymphocytic infiltrations at the margins of lesions in the majority of patients has lent support to the hypothesis that it is an autoimmune disease [2–5].
Many self proteins expressed by melanocytes in the skin of healthy donors, in non-depigmented skin of vitiligo patients and in melanoma patients are demonstrably immunogenic [6–8]. Antigens present in both tumor cells (melanoma) and their normal cellular counterpart (melanocytes) are known as melanocyte differentiation antigens. Among these, Melan-A/MART-1 is a melanosomal protein whose immunodominant epitope for HLA-A*0201 was identified by a screening with cytotoxic T cells .
High frequencies of melanocyte-specific CD8+ T lymphocytes are found in vitiligo patients. Using HLA/epitope tetramers, an instrument for measuring the frequency of antigen-specific T cells independently of their functional state , Ogg and co-authors  directly demonstrated for the first time the presence of high frequencies of CD8+ T cells specific for melanocytic antigens in the peripheral blood of HLA-A*0201+ patients with autoimmune vitiligo. Following this pioneering study, other groups [reviewed in [12–14]] contributed, through the use of tetramers directly ex vivo, without any antigen-specific stimulation, to the demonstration that melanocyte-specific CD8+ cells are present in the peripheral blood of both melanoma and vitiligo patients. In particular, high numbers of Melan-A/MART1-specific cells were detected in the majority of patients. Besides circulating cells, melanocyte-specific CD8+ T lymphocytes were also observed in situ in both depigmenting lesions of patients with vitiligo [15, 16].
These melanocyte-specific CD8+ T Lymphocytes might be relevant for the pathogenesis of vitiligo. The first suggestions came from rare case reports on inflammatory vitiligo [17, 18] and immunohistochemical studies later on confirmed the presence of infiltrating T cells in apposition to perilesional melanocytes . Importantly, similar in situ T cell infiltrates were also detected in the more common form of the disease, generalized vitiligo [20–22]. Further indications favoring a pathogenetic role for melanocyte-specific, CD8+ T cells in vitiligo came from the direct correlation between their frequency within the total T cell pool and disease activity [11, 23], as well as from their capacity to kill HLA-matched tumor cells [11, 24, 25] and, most notably, normal matched melanocytes [16, 26].
Melanoma is an aggressive form of tumor whose incidence increases by 5% per year. Although the presence of melanoma-specific CTLs in cancer patients demonstrate that tumor cells may not completely evade immune recognition, the patient's immune system can only rarely counteract tumor growth [27–29]. An unusual facet of vitiligo is its relation to melanoma: cytotoxic T lymphocytes directed at self antigens shared by normal melanocytes and melanoma cells are found in both conditions and suggest a breakdown of tolerance [11, 30–34], yet the resulting immune reaction is the opposite [35–37]. In vitiligo, natural immune tolerance is over-ridden such that the host immune system can orchestrate melanocyte destruction, whereas in melanoma, an immune effector function of potential benefit to the host, i.e., efficient destruction of transformed melanocytes, does occur very rarely. In this respect, it would seem that reactivity to vitiligo melanocytes may be the effective variant of an immune response often ineffective in melanoma. The mechanisms causing these opposite effects are not known but these data, together with the resistance of melanoma to conventional chemotherapeutic and radiotherapeutic approaches, have made the melanoma/vitiligo dichotomy an important model for immunologic investigation.
Avidity of antigen recognition is an important feature of tumor-specific T lymphocytes, determining their capability to kill tumor cells. Notably, a few recent studies indicated that Melan-A/MART1-specific CD8+ T cells isolated from vitiligo patients possess an increased avidity and exert a superior anti-tumor activity than those from melanoma [24, 25]. Further indications come from animal models. In one recent study  MT-ret transgenic mice, a model for human cutaneous melanoma, were used to investigate the natural anti-tumor T cell response. A large proportion of these animals developed melanoma-associated vitiligo and a good correlation was found between vitiligo development and melanoma control. Interestingly, T cells that secreted IFN-γ in response to melanoma cells were statistically more frequent in melanoma mice that developed vitiligo than in mice that did not, suggesting that vitiligo-associated T cells possessed an increased functional avidity. These data suggest that a qualitative difference exists between the anti-melanocyte cytotoxic T cell responses found in vitiligo versus melanoma that might explain the opposite immunologic outcomes.
Autoimmune conditions stem from a break of tolerance to defined autoantigens and this allows for the production of high avidity antigen-specific responses. If these antigens are also relevant to tumor immunity, autoimmune cells can be exploited for tumor intervention. Our working hypothesis is that vitiligo patients might represent a unique source of therapeutic cells for HLA-matched melanoma patients, essentially due to their superior TCR affinity and increased tumoricidal potential.
The adoptive transfer of ex-vivo generated autologous tumor-specific T cells is a potentially potent therapy that has met with only limited success. An important limitation to such treatment is inability to isolate and generate therapeutically valuable T cells from the majority of tumor patients. The causes of these limitations are not well known, but might include the inability of the tumor cells to trigger a T-cell response (ignorance) or their ability to actively suppress or delete T cells of the highest avidity (tolerance). In addition, T cells derived from melanoma patients may often display functional impairments as a consequence of the tumor environment, which inhibits their acquisition of final effector functions . Indeed, in vitro culture of these tumor-sensitized T cells with appropriate activation stimuli has been shown to partially restore normal functional properties  and to confer effector activity that could potentially sustain tumor rejection upon re-infusion . However, in the majority of cases, autologous T cells are found to exert only poor cytotoxic activity toward HLA matched melanoma cells. On the other hand, CTLs against different melanoma associated antigen are found in vitiligo and mediate autologous melanocyte destruction [24–26, 30, 31]. Notably, the Melan-A/MART1-specific CD8+ T cells isolated from vitiligo patients appear to possess an increased avidity and to exert a superior anti-tumor activity than those from melanoma [24–26].
How can this knowledge be applied to the definition of new immunotherapeutic strategies for melanoma patients? A first possibility is an allo-transfer approach, where very efficient anti-tumor CD8+ T lymphocytes from vitiligo donors can be transferred into HLA-matched melanoma patients. High-avidity and tumor-specific T cell clones can be isolated from the peripheral blood of HLA-A2 vitiligo patients; if these could be proven to efficiently expand in vitro without loosing their cytotoxic activity and to maintain their skin-homing capability, they might represent a valuable source of therapeutic cells.
In order to test the hypothesis, melanocyte-specific T cell clones could be tetramer-sorted from the peripheral blood of vitiligo patients and tested for their capacity to efficiently expand in vitro without loosing their cytotoxic activity. They will also be tested for their skin-homing activity by FACS-evaluating surface expression of the cutaneous lymphocyte antigen, CLA. As a first effort in determining the effects of host cellular environment on allo-transfer, these cells can be mixed with PBMC from HLA-matched melanoma patients and the anti-tumor potential of the vitiligo/melanoma pools assayed. Possible immunosuppressor effects exerted by either the melanoma patients' sera  or the tumor itself might be addressed through co-cultures. Cytotoxicity against melanoma patients' non-tumor cells (peripheral blood, skin biopsies) can also be tested. In addition, it would be interesting to attempt an in vivo animal model using immunodeficient SCID or RAG knockout mice, rendered transgenic for human HLA and transplanted with melanoma. These mice might be treated with the clone from a vitiligo patient, with or without melanoma patient's lymphocytes. If the results obtained from both the in vitro validation step and the in vivo animal model will be satisfactory, it will be possible to plan the clinical grade preparation of relevant clones for transfer. A major drawback of this approach remains achievement of HLA match between a T cell donor and a melanoma patient. Only weak associations between vitiligo and several HLA-class I and -class II alleles have been reported to date, and essentially no significant association exists with melanoma. So, as patients with vitiligo represent about 1% of the general population, the probability to find a perfect match can be estimated to be a hundred-time lower than the one theoretically achieved for allogeneic transplantation involving the entire population as potential donors.
If this hypothesis were true, at least some autoimmune diseases might be seen as novel sources of therapeutic cells for tumor patients. When translated into a clinical trial, the possibility of in vitro selecting few tumor-specific T cell clones for infusion, inherent with this approach, could enhance the therapeutic graft-versus-tumor effect while possibly decreasing the risk of graft-versus-host disease.
This work was partially supported by Associazione Italiana per la Ricerca sul Cancro (AIRC). S.G. was supported by a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC). We are grateful to melanoma and vitiligo patients for their generous participation in this research project.
- Njoo MD, Westerhof W: Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol. 2001, 2: 167-181. ReviewView ArticlePubMedGoogle Scholar
- Bystryn JC: Immune mechanisms in vitiligo. Clin Dermatol. 1997, 15: 853-861. 10.1016/S0738-081X(97)00126-0. ReviewView ArticlePubMedGoogle Scholar
- Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, Nickoloff BJ, Das PK: Autoimmune aspects of depigmentation in vitiligo. J Invest Dermatol Symp Proc. 2004, 9: 68-72. 10.1111/j.1087-0024.2004.00825.x.View ArticleGoogle Scholar
- Ongenae K, van Geel N, Naeyaert J-M: Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003, 16: 90-100. 10.1034/j.1600-0749.2003.00023.x.View ArticlePubMedGoogle Scholar
- van den Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P: Autoimmune melanocyte destruction in vitiligo. Lab Invest. 2001, 81: 1061-1067.View ArticlePubMedGoogle Scholar
- Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G: Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993, 177: 989-998. 10.1084/jem.177.4.989.View ArticlePubMedGoogle Scholar
- Le Poole IC, Mutis T, van den Wijngaard RM, Westerhof W, Ottenhoff T, de Vries RR, Das PK: A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol. 1993, 151: 7284-7292.PubMedGoogle Scholar
- Meije CB, Mooi WJ, Le Poole IC, Van Muijen GN, Das PK: Micro-anatomy related antigen expression in melanocytic lesions. J Pathol. 2000, 190: 572-578. 10.1002/(SICI)1096-9896(200004)190:5<572::AID-PATH570>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
- Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994, 180: 347-352. 10.1084/jem.180.1.347.View ArticlePubMedGoogle Scholar
- Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996, 274: 94-96. 10.1126/science.274.5284.94.View ArticlePubMedGoogle Scholar
- Ogg GS, Dunbar R, Romero P, Chen JL, Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998, 188: 1203-1208. 10.1084/jem.188.6.1203.PubMed CentralView ArticlePubMedGoogle Scholar
- Ogg GS: Detection of antigen-specific cytotoxic T lymphocytes: significance for investigative dermatology. Clin Exp Dermatol. 2000, 25: 312-316. 10.1046/j.1365-2230.2000.00651.x. ReviewView ArticlePubMedGoogle Scholar
- Parmiani G: Melanoma antigens and their recognition by T cells. Keio J Med. 2001, 50: 86-90. ReviewView ArticlePubMedGoogle Scholar
- Palmowski M, Salio M, Dunbar RP, Cerundolo V: The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol Rev. 2002, 188: 155-163. 10.1034/j.1600-065X.2002.18814.x. ReviewView ArticlePubMedGoogle Scholar
- Becker JC, Guldberg P, Zeuthen J, Brocker EB, Straten PT: Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol. 1999, 113: 1033-1038. 10.1046/j.1523-1747.1999.00805.x.View ArticlePubMedGoogle Scholar
- Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, Storkus WJ, Das PK: Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest. 2003, 83: 683-695.View ArticlePubMedGoogle Scholar
- Buckley WR, Lobitz WC: [Vitiligo with a raised inflammatory border.]. AMA Arch Derm Syphilol. 1953, 67: 316-320.View ArticlePubMedGoogle Scholar
- Michaelsson G: Vitiligo with raised borders. Report of two cases. Acta Derm Venereol. 1968, 48: 158-161.PubMedGoogle Scholar
- Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK: Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996, 148: 1219-1228.PubMed CentralPubMedGoogle Scholar
- al Badri AM, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudie RB: An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol. 1993, 170: 149-155. 10.1002/path.1711700209.View ArticleGoogle Scholar
- Abdel-Naser MB, Kruger-Krasagakes S, Krasagakis K, Gollnick H, Abdel-Fattah A, Orfanos CE: Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res. 1994, 7: 1-8.View ArticlePubMedGoogle Scholar
- van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P: Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest. 2000, 80: 1299-1309.View ArticlePubMedGoogle Scholar
- Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C: HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol. 2001, 116: 891-897. 10.1046/j.1523-1747.2001.01363.x.View ArticlePubMedGoogle Scholar
- Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigo M, Borroni G, Martinetti M, Badulli C, et al: Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol. 2001, 117: 326-332. 10.1046/j.1523-1747.2001.01408.x.View ArticlePubMedGoogle Scholar
- Mantovani S, Palermo B, Garbelli S, Campanelli R, Robustelli Della Cuna G, Gennari R, Benvenuto F, Lantelme E, Giachino C: Dominant TCR-alpha requirements for a self antigen recognition in humans. J Immunol. 2002, 169: 6253-6260.View ArticlePubMedGoogle Scholar
- Mantovani S, Garbelli S, Palermo B, Campanelli R, Brazzelli V, Borroni G, Martinetti M, Benvenuto F, Merlini G, Robustelli della Cuna G, et al: Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. J Invest Dermatol. 2003, 121: 308-134. 10.1046/j.1523-1747.2003.12368.x.View ArticlePubMedGoogle Scholar
- Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995, 16: 487-494. 10.1016/0167-5699(95)80033-6. ReviewView ArticlePubMedGoogle Scholar
- Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, et al: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996, 274: 1363-1366. 10.1126/science.274.5291.1363.View ArticlePubMedGoogle Scholar
- Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT: Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest. 1996, 98: 1633-1641.PubMed CentralView ArticlePubMedGoogle Scholar
- Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000, 192: 1637-1644. 10.1084/jem.192.11.1637.PubMed CentralView ArticlePubMedGoogle Scholar
- Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG: Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001, 117: 1464-1470. 10.1046/j.0022-202x.2001.01605.x.View ArticlePubMedGoogle Scholar
- Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, et al: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev. 2002, 188: 97-113. 10.1034/j.1600-065X.2002.18809.x. ReviewView ArticlePubMedGoogle Scholar
- Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, et al: Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002, 188: 81-96. 10.1034/j.1600-065X.2002.18808.x. ReviewView ArticlePubMedGoogle Scholar
- Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA: Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol. 2003, 121: 550-556. 10.1046/j.1523-1747.2003.12413.x.View ArticlePubMedGoogle Scholar
- Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC: A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends in Immunology. 2001, 22: 130-136. 10.1016/S1471-4906(00)01844-5.View ArticlePubMedGoogle Scholar
- Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN: Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene. 2003, 22: 3180-3187. 10.1038/sj.onc.1206462.View ArticlePubMedGoogle Scholar
- Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK: Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?. Pigment Cell Res. 2003, 16: 254-260. 10.1034/j.1600-0749.2003.00038.x. ReviewView ArticlePubMedGoogle Scholar
- Lengagne R, Le Gal FA, Garcette M, Fiette L, Ave P, Kato M, Briand JP, Massot C, Nakashima I, Renia L, et al: Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer Res. 2004, 64: 1496-1501.View ArticlePubMedGoogle Scholar
- Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, et al: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol. 1995, 154: 2257-2265.PubMedGoogle Scholar
- Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994, 86: 1159-1166.View ArticlePubMedGoogle Scholar
- Juranic ZD, Stanojevic-Bakic N, Zizak Z, Babovic N, Radovic-Kovacevic V, Stanojkovic T, Dzodic R: Antimelanoma immunity in vitiligo and melanoma patients. Neoplasma. 2003, 50: 305-309.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.